Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

NISOLDIPINE

NISOLDIPINE

Standard Dose
34MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview NISOLDIPINE is listed in Drugs@FDA under application 091001 (ANDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient NISOLDIPINE Form and strength TABLET, EXTENDED RELEASE;ORAL - 34MG Sponsor MYLAN Submission history Latest submission status date: 2022-08-11 00:00:00.

Structured Monograph

Clinical summary

Approval overview NISOLDIPINE is listed in Drugs@FDA under application 091001 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient NISOLDIPINE Form and strength TABLET, EXTENDED RELEASE;ORAL - 34MG Sponsor MYLAN Submission history Latest submission status date: 2022-08-11 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.